Trial intelligence / Profile preview

ADYNOVATE prophylaxis and on-demand treatment in previously treated Chinese patients with severe hemophilia A

CTR20223385Phase 3Completed

Sponsor
Takeda
Start
Jan 2023
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

A Phase 3 trial of recombinant coagulation factor viii in hemophilia A, sponsored by Takeda. Started Jan 2023; status: completed.

02

Drugs

recombinant coagulation factor viii
03

Conditions

hemophilia A

Beyond the preview

Go deeper on CTR20223385.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20223385.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call